Two Novel Product Platforms

FLAG Therapeutics, Inc. is an early-stage oncology company focused on the development of therapies based on two investigational product platforms:

  • Anti-angiogenic/Anti-tubulin (AA/AT) Compounds:  Investigational water-soluble small molecule drugs designed to harness the power of two well-understood anti-cancer activities into one molecular function.
    • Brain Cancer (GBM)
    • Triple Negative Breast Cancer (TNBC)
       
  • Folate-targeted Anti-cancer (FTAC) Compounds:  Investigational water-soluble small molecule drugs designed to specifically target and destroy tumor cells.
    • Mesothelioma
    • Pancreatic Cancer

Latest News

FLAG Therapeutics awarded $1,500,000 Phase II SBIR - Development of Novel Targeted Chemotherapeutics for the Treatment of Malignant Pleural Mesothelioma

FLAG Therapeutics awarded 8 additional patents in 2017

Upcoming Keiretsu Forum Presentations

3/13/2018 - Miami

3/14/2018 - Atlanta

3/20/2018 - New York City

3/21/2018 - Philadelphia

3/22/2018 - Washington, DC

3/23/2018 - Pittsburgh